ANTI-B2M ANTIBODY MOUSE MONOCLONAL

Code: SAB4200785-100UL D2-231

Application

Immunoblotting: a working concentration of 0.1-0.2 µg/mL is recommended using β2-Microglobulin from human urine.Immunoprecipitation: a working concentra...


read more

Your Price
€500.00 100UL
€615.00 inc. VAT

Application

Immunoblotting: a working concentration of 0.1-0.2 µg/mL is recommended using β2-Microglobulin from human urine.Immunoprecipitation: a working concentration of 2.5-5 µg/test is recommended using lysate of human HeLa cell line. Indirect ELISA: a working concentration of 0.2-0.4 µg/mL is recommended using 1 µg/mL ß2-Microglobulin from human urine for coating.

General description

B2M (β2-Microglobulin) is the light chain of the major histocompatibility class (MHC) I molecule expressed on the cell surface of all nucleated cells, including lymphocytes, thymocytes, monocytes, granulocytes, platelets, endothelial cells and epithelial cells and is absent in erythrocytes. B2M is filtered during glomerular filtrations and re-absorbed and catabolized by proximal renal tubule. While under normal conditions the B2M is undetectable in urine, its increased urinary excretion has been observed to be an early marker of tubular injury in a number of settings, including nephrotoxicant exposure, cardiac surgery and renal transplantation, preceding rises in serum creatinine by as many as 4-5 days. B2M may also serve as an early biomarker for AKI (Acute Kidney Injury). B2M plays a vital role in cell survival, proliferation and metastasis in various types of cancer. Its levels are also linked with multiple myeloma (MM) and non-Hodgkin′s lymphoma (NHL). NHL patients showing higher levels of B2M have a poor disease prognosis and a higher mortality risk. The protein has a predominantly β-pleated sheet structure that can form amyloid fibrils in some pathological conditions. In patient subjected to long-term hemodialysis, B2M is responsible for systemic amyloidosis. The levels of this protein are also altered in the cerebrospinal fluid of patients with neurological diseases, such as leptomeningeal metastasis, purulent meningitis, viral meningitis or encephalitis and neuroborreliosis. Over-expression of serum B2M is observed in hepatitis C virus (HCV) related chronic liver diseases and thus acts as a potential marker for the HCV disease progression towards cirrhosis and carcinoma.

Immunogen

Recombinant B2M protein.

Other Notes

In order to obtain best results in different techniques and preparations we recommend determining optimal working concentration by titration test.

Physical form

Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15mM sodium azide.

antibody formpurified from hybridoma cell culture
antibody product typeprimary antibodies
biological sourcemouse
clone92A, monoclonal
concentration~1 mg/mL
formbuffered aqueous solution
Gene Informationhuman ... B2M(567)
isotypeIgG2a
mol wt~15 kDa
Quality Level200
shipped indry ice
species reactivityhuman
storage temp.−20°C
technique(s)immunoprecipitation (IP): 2.5-5 µg/test using lysate of human HeLa cell line., immunoblotting: 0.1-0.2 µg/mL using β2-Microglobulin from human urine., indirect ELISA: 0.2-0.4 µg/mL using 1 µg/ml β2-Microglobulin from human urine for coating.
UniProt accession no.P61769
This product has met the following criteria to qualify for the following awards:



PROCEED TO CHECKOUT

HAVE AN ACCOUNT? LOGIN


GUEST CHECKOUT

Proceed as a guest. You will have the option to register to access exclusive pricing and stock availability features after checkout.